Cellular Therapies in Acute Lymphoblastic Leukemia

Hematology/Oncology Clinics of North America

Volumn 25, Issue 6, 2011, Pages 1281-1301

  Park, Jae H ^a,b   Sauter, Craig ^a,b   Brentjens, Renier ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute lymphoblastic leukemia; Adoptive cellular therapy; Chimeric antigen receptor; Hematopoietic stem cell transplants

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DASATINIB; FLUDARABINE; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA REMISSION; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REVIEW;

ADOPTIVE TRANSFER; ANIMALS; CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION CONDITIONING;

EID: 81255211097     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.09.015     Document Type: Review

References (119)

1. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354(2):166-178.
2. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371(9617):1030-1043.
3. Fielding A.K., Richards S.M., Chopra R., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109(3):944-950.
4. Gaynon P.S. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005, 131(5):579-587.
5. Tavernier E., Boiron J.M., Huguet F., et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007, 21(9):1907-1914.
6. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300(19):1068-1073.
7. Porter D.L., Antin J.H. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999, 50:369-386.
8. Gokbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009, 46(1):64-75.
9. Larson R. Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplant 2008, 42(Suppl 1):S18-S24.
10. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006, 12(1):1-30.
11. Thiebaut A., Vernant J.P., Degos L., et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000, 14(6):1353-1366. x.
12. Thomas X., Boiron J.M., Huguet F., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004, 22(20):4075-4086.
13. Yanada M., Matsuo K., Suzuki T., et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006, 106(12):2657-2663.
14. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111(4):1827-1833.
15. Ribera J.M., Oriol A., Bethencourt C., et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005, 90(10):1346-1356.
16. Fielding A.K., Rowe J.M., Richards S.M., et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009, 113(19):4489-4496.
17. Lee H.J., Thompson J.E., Wang E.S., et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011, 117(8):1583-1594.
18. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109(4):1408-1413.
19. Lee S., Kim D.W., Kim Y.J., et al. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2003, 102(8):3068-3070.
20. Fielding A.K., Buck G., Lazarus H.M., et al. Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia; final results of the UKALL XII/ECOG 2993 Trial. Blood 2010, 16(21):77.
21. Mizuta S., Matsuo K., Yagasaki F., et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011, 25(1):41-47.
22. Huguet F., Leguay T., Raffoux E., et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009, 27(6):911-918.
23. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107(3):1116-1123.
24. Bassan R., Spinelli O., Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113(18):4153-4162.
25. Goekbuget N., Brueggemann M., Arnold R., et al. New definition of treatment response in adult acute lymphoblastic leukemia (ALL): use of molecular marker s for minimal residual disease (MRD). Blood 2009, 114(22):42.
26. Beldjord K., Lheritier V., Boulland M.L., et al. Post-induction minimal residual disease (MRD) defines a large subset of adults with favorable Philadelphia negative acute lymphoblastic leukemia (ALL), who do not benefit from allogeneic stem cell transplantation (SCT) in first complete remission: a GRAALL study. Blood 2009, 114(22):239.
27. Ribera J.M., Oriol A., Morgades M., et al. Treatment of high-risk (HR) Philadelphia chromosome-negative (Ph-) adult acute lymphoblastic leukemia (ALL) according to baseline risk factors and minimal residual disease (MRD): Results of the PETHEMA ALL-AR-03 trial including the use of propensity score (PS) method to reduce assignment bias. Blood 2009, 114(22):136.
28. Marks D.I., Cullis J.O., Ward K.N., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993, 119(3):207-214.
29. Beatty P.G., Anasetti C., Hansen J.A., et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993, 81(1):249-253.
30. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998, 92(10):3515-3520.
31. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363(22):2091-2101.
32. Ottinger H.D., Ferencik S., Beelen D.W., et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood 2003, 102(3):1131-1137.
33. Walter R.B., Pagel J.M., Gooley T.A., et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010, 24(7):1276-1282.
34. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006, 24(36):5695-5702.
35. Chim C.S., Lie A.K., Liang R., et al. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor. Bone Marrow Transplant 2007, 40(4):339-347.
36. Dahlke J., Kroger N., Zabelina T., et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006, 37(2):155-163.
37. Kiehl M.G., Kraut L., Schwerdtfeger R., et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22(14):2816-2825.
38. Nishiwaki S., Inamoto Y., Sakamaki H., et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010, 116(20):4368-4375.
39. Sauter C., Barker J.N. Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies. Curr Opin Hematol 2008, 15(6):568-575.
40. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351(22):2265-2275.
41. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351(22):2276-2285.
42. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004, 104(12):3813-3820.
43. Barker J.N., Rocha V., Scaradavou A. Optimizing unrelated donor cord blood transplantation. Biol Blood Marrow Transplant 2008, 15(Suppl 1):154-161.
44. Barker J.N., Byam C., Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011, 117(8):2332-2339.
45. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105(3):1343-1347.
46. Haspel R.L., Ballen K.K. Double cord blood transplants: filling a niche?. Stem Cell Rev 2006, 2(2):81-86.
47. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114(19):4293-4299.
48. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010, 11(7):653-660.
49. Atsuta Y., Suzuki R., Nagamura-Inoue T., et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009, 113(8):1631-1638.
50. Kumar P., Defor T.E., Brunstein C., et al. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol Blood Marrow Transplant 2008, 14(12):1394-1400.
51. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008, 41(5):473-481.
52. Aversa F., Tabilio A., Terenzi A., et al. Successful engraftment of T-cell-depleted haploidentical " three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994, 84(11):3948-3955.
53. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339(17):1186-1193.
54. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23(15):3447-3454.
55. Ciceri F., Labopin M., Aversa F., et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112(9):3574-3581.
56. Huang X.J., Liu D.H., Liu K.Y., et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15(2):257-265.
57. Barrett J., Gluckman E., Handgretinger R., et al. Point-counterpoint: haploidentical family donors versus cord blood transplantation. Biol Blood Marrow Transplant 2011, 17(Suppl 1):S89-S93.
58. Ballen K.K., Spitzer T.R. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant 2011, 46(3):323-329.
59. Arnold R., Massenkeil G., Bornhauser M., et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002, 16(12):2423-2428.
60. Martino R., Giralt S., Caballero M.D., et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003, 88(5):555-560.
61. Ram R., Storb R., Sandmaier B.M., et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011, 96(8):1113-1120.
62. Stein A.S., Palmer J.M., O'Donnell M.R., et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009, 15(11):1407-1414.
63. Marks D.I., Wang T., Perez W.S., et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010, 116(3):366-374.
64. Mohty M., Labopin M., Volin L., et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010, 116(22):4439-4443.
65. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110(8):3064-3070.
66. Bachanova V., Verneris M.R., DeFor T., et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009, 113(13):2902-2905.
67. Small T.N., Papadopoulos E.B., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999, 93(2):467-480.
68. Jakubowski A.A., Small T.N., Kernan N.A., et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 2011, 17(9):1335-1342.
69. Patel B., Kirkland K.E., Szydlo R., et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 2009, 94(10):1399-1406.
70. O'Brien S., Thomas D., Ravandi F., et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008, 113(11):3186-3191.
71. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995, 86(5):2041-2050.
72. Kolb H.J., Schmid C., Barrett A.J., et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103(3):767-776.
73. Loren A.W., Porter D.L. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008, 41(5):483-493.
74. Choi S.J., Lee J.H., Lee J.H., et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant 2005, 36(2):163-169.
75. Collins R.H., Goldstein S., Giralt S., et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000, 26(5):511-516.
76. Porter D.L., Levine B.L., Bunin N., et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006, 107(4):1325-1331.
77. Oka Y., Elisseeva O.A., Tsuboi A., et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000, 51(2):99-107.
78. Oka Y., Udaka K., Tsuboi A., et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000, 164(4):1873-1880.
79. Rezvani K., Yong A.S., Savani B.N., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110(6):1924-1932.
80. Brentjens R.J. Novel Approaches to Immunotherapy for B-cell Malignancies. Curr Oncol Rep 2004, 6(5):339-347.
81. Sadelain M., Brentjens R., Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21(2):215-223.
82. Sadelain M., Riviere I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3(1):35-45.
83. Johnson L.A., Morgan R.A., Dudley M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
84. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
85. Dossett M.L., Teague R.M., Schmitt T.M., et al. Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol Ther 2009, 17(4):742-749.
86. Xue S.A., Gao L., Hart D., et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005, 106(9):3062-3067.
87. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of " tumor escape" phenotypes. Nat Immunol 2002, 3(11):999-1005.
88. Gottschalk S., Ng C.Y., Perez M., et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001, 97(4):835-843.
89. Park J.H., Brentjens R.J. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010, 9(47):277-288.
90. Hollyman D., Stefanski J., Przybylowski M., et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009, 32(2):169-180.
91. Singh H., Figliola M.J., Dawson M.J., et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011, 71(10):3516-3527.
92. Tammana S., Huang X., Wong M., et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 2010, 21(1):75-86.
93. Kowolik C.M., Topp M.S., Gonzalez S., et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006, 66(22):10995-11004.
94. Hoyos V., Savoldo B., Quintarelli C., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24(6):1160-1170.
95. Chmielewski M., Kopecky C., Hombach A.A., et al. IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression. Cancer Res 2011, 71(17):5697-5706.
96. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003, 9(3):279-286.
97. Brentjens R.J., Santos E., Nikhamin Y., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007, 13(18 Pt 1):5426-5435.
98. Cooper L.J., Al-Kadhimi Z., DiGiusto D., et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004, 33(1):83-89.
99. Cooper L.J., Al-Kadhimi Z., Serrano L.M., et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005, 105(4):1622-1631.
100. Cooper L.J., Topp M.S., Serrano L.M., et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003, 101(4):1637-1644.
101. Imai C., Mihara K., Andreansky M., et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18(4):676-684.
102. Loskog A., Giandomenico V., Rossig C., et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006, 20(10):1819-1828.
103. Rossig C., Bollard C.M., Nuchtern J.G., et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002, 99(6):2009-2016.
104. Topp M.S., Kufer P., Gokbuget N., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29(18):2493-2498.
105. Milone M.C., Fish J.D., Carpenito C., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009, 17(8):1453-1464.
106. Kochenderfer J.N., Feldman S.A., Zhao Y., et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009, 32(7):689-702.
107. Wang J., Jensen M., Lin Y., et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007, 18(8):712-725.
108. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20):4099-4102.
109. Brentjens R.J., Riviere I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, [Epub ahead of print].
110. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365(8):725-733.
111. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3(95):95ra73.
112. Savoldo B., Micklethwaite K., Cooper L., et al. Monoculture-derived T lymphocytes providing multiple virus specificity and anti-leukemia activity for recipients of hematopoietic stem cells or umbilical cord blood transplants. Blood 2008, 112(11):3909. [abstract 3909].
113. Serrano L.M., Pfeiffer T., Olivares S., et al. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 2006, 107(7):2643-2652.
114. Micklethwaite K.P., Savoldo B., Hanley P.J., et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010, 115(13):2695-2703.
115. Grzywacz B., Miller J.S., Verneris M.R. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol 2008, 21(3):467-483.
116. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295(5562):2097-2100.
117. Fujisaki H., Kakuda H., Shimasaki N., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69(9):4010-4017.
118. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106(1):376-383.
119. Li L., Liu L.N., Feller S., et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 2010, 17(3):147-154.